An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Influenza, Human Clinical Trial

Official title:

An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04494412
• Other study ID #: 200925
• Status: Recruiting
• Phase: Phase 2
• Start date: November 21, 2022
• Est. completion date: December 9, 2026

Study information

• Verified date: January 2024
• Source: GlaxoSmithKline
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more than or equal to (>=) 6 months of age with hospitalized influenza in the IV zanamivir global development program. However, antiviral treatment of neonates and infants under 6 months of age hospitalized with influenza infection remains a medical unmet need. Given the immaturity of the immune system at this age, there are no licensed influenza vaccines for children aged less than six months old. As a requirement of the Pediatric Investigation Plan European Union (EU), GlaxoSmithKline (GSK) will be conducting this open-label, multi-center, single arm, post-marketing authorization study to evaluate the PK and collect safety and tolerability information of IV zanamivir in hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection. The total duration of study participation for each participant will be up to 24 days with a study treatment period up to 10 days and 14 days of post-treatment follow up. However, for a given participant, the initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests as assessed by the investigator warrant further treatment. DECTOVA is a trademark of GlaxoSmithKline group of companies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 9, 2026
• Est. primary completion date: December 9, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 6 Months

Eligibility

Inclusion Criteria:

• Neonates and infants who are aged less than 6 months (corrected age) at the time of the informed consent signed by legally acceptable representative (LAR) of minors. Preterm neonates and infants will be eligible for inclusion but must have reached PMA of at least 28 weeks.

• Participants who are hospitalized with influenza infection, confirmed by a positive rapid molecular diagnostic test for influenza, or a local quantitative Reverse transcriptase-polymerase chain reaction (RT-PCR) test and who must have a potential for improvement Participants with negative rapid molecular test result suspected of having influenza can be enrolled following confirmatory testing by quantitative RT-PCR.

• Participants with a high risk of altered oral drug absorption, represented by multi-organ dysfunction (dysfunction of at least 2 organs, as defined by the treating physician). (applicable only for Netherlands)

• Body weight >=1 kilograms (kg).

• No gender restriction.

• LAR of minors are willing and able to give written informed consent to participate in the study (or included as permitted by local regulatory authorities, Independent Ethics Committees [IECs] or local laws).

Exclusion criteria:

• Participants who are known or suspected to be hypersensitive to any component of the study medication.

• Participants with a disease process which is likely to be irreversible.

• Liver function:

• Participants who meet the following criteria at Baseline:

1. Alanine transaminase (ALT) >=3 times upper limit of normal (ULN) with bilirubin >=2 times ULN

2. or isolated bilirubin >=2 times ULN and >50 percent (%) direct bilirubin

3. or ALT >=5 times ULN Inclusion of participants with liver function tests that fall outside these criteria must be discussed and agreed with the medical monitor.

• Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of benign conditions such as Gilbert's syndrome). Inclusion of participants with neonatal hyperbilirubinemia may be considered if appropriately managed according to local guidelines and must be discussed with the medical monitor (Not-applicable for Great Britain).

• Participants who require concurrent therapy with another anti influenza drug.

• Participants who have participated in a study using an investigational drug within 30 days prior to Baseline.

• Child in care (CiC), as defined below:

• A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.

• The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a CiC does not include a child who is adopted or has an appointed legal guardian.

• Participants undergoing treatment by Extracorporeal membrane oxygenation (ECMO) or hemofiltration.

• Participants who are positive for severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) as determined by a diagnostic test, at screening

Related Conditions & MeSH terms

• Arthralgia
• Influenza, Human

Intervention

Drug:
• Zanamivir
Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.

Locations

Country	Name	City	State
Netherlands	GSK Investigational Site	Nijmegen
Poland	GSK Investigational Site	Bydgoszcz
Spain	GSK Investigational Site	Esplugues De Llobregat. Barcelona
Spain	GSK Investigational Site	Madrid
United Kingdom	GSK Investigational Site	Dundee
United Kingdom	GSK Investigational Site	London
United Kingdom	GSK Investigational Site	London

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Netherlands,  Poland,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the serum concentration-time curve (AUC) of zanamivir	Blood samples will be collected at indicated time points for pharmacokinetic analysis of zanamivir.	Up to 12 hours after end of infusion on Day 1
Primary	Maximum observed serum concentration (Cmax) of zanamivir	Blood samples will be collected at indicated time points for pharmacokinetic analysis of zanamivir.	Up to 12 hours after end of infusion on Day 1
Primary	Clearance (CL) in plasma following administration of zanamivir	Blood samples will be collected at indicated time points for pharmacokinetic analysis of zanamivir.	30 minutes, 2 hours, 6 hours, 12 hours post dose on Day 1; predose on Days 3, 4 or 5
Primary	Terminal half-life (t1/2) of zanamivir	Blood samples will be collected at indicated time points for pharmacokinetic analysis of zanamivir.	30 minutes, 2 hours, 6 hours, 12 hours post dose on Day 1; predose on Days 3, 4 or 5
Secondary	Number of participants with adverse event(s) (AE) and serious adverse event(s) (SAE)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect or any other important medical event that may jeopardize the participant or may require medical or surgical treatment to prevent one of the other outcomes listed before.	From start of treatment (Day 1) up to Day 24
Secondary	Number of participants with abnormal findings in heart rate	Number of participants with abnormal findings for heart rate will be assessed.	From start of treatment (Day 1) up to Day 24
Secondary	Number of participants with abnormal findings in Oxygen Saturation	Number of participants with abnormal findings for Oxygen Saturation will be assessed.	From start of treatment (Day 1) up to Day 24
Secondary	Number of participants with abnormal findings in respiration rate	Number of participants with abnormal findings for respiration rate will be assessed.	From start of treatment (Day 1) up to Day 24
Secondary	Number of participants with abnormal findings in body temperature	Number of participants with abnormal findings for body temperature will be assessed.	From start of treatment (Day 1) up to Day 24
Secondary	Viral load over time after administration of zanamivir	Nasopharyngeal swab samples will be collected for assessing quantitative viral load.	Day 1 up to Maximum Day 24
Secondary	Change From Baseline in viral load after administration of zanamivir	Nasopharyngeal swab samples will be collected for assessing quantitative viral load.	Baseline (Day 1) and up to maximum Day 24
Secondary	Number of participants with phenotypic resistance	Nasopharyngeal swab samples will be collected for assessing phenotypic resistance.	Up to Day 24
Secondary	Number of participants with genotypic resistance	Nasopharyngeal swab samples will be collected for assessing genotypic resistance.	Up to Day 24
Secondary	Number of participants with emergence of resistance to zanamivir	Nucleotide sequence analysis will be carried out to determine emergence of resistance to zanamivir.	Up to Day 24